I-FABP as a Predictor of Gut Involvement in Pediatric IgA Vasculitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational cohort study in children with IgA vasculitis. Researchers will measure plasma I-FABP at diagnosis and at a 2–4 week follow-up to see if levels are linked to gastrointestinal involvement. Participants will be followed with routine clinical care, and no new treatments will be given as part of the study. Data on clinical features, labs, and demographics will be analyzed to determine the association between I-FABP and GI involvement. The aim is to explore I-FABP as a noninvasive biomarker for early detection and assessment of GI involvement in pediatric patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of IgA vasculitis (Henoch-Schönlein purpura) according to EULAR/PRINTO/PRES classification criteria.
* Age between 2 and 18 years.
* Availability for blood sample collection at diagnosis (baseline visit).
* Ability to attend a routine follow-up visit approximately 2-4 weeks after diagnosis.
* Parent or legal guardian able and willing to provide written informed consent.

Exclusion Criteria:

* Refusal of informed consent by the parent/legal guardian.
* Inability to obtain a baseline blood sample.
* Inability to complete study follow-up procedures.

Where it's running

• Bursa City Hospital
  Bursa, Bursa, Turkey (Türkiye) Recruiting

Study contacts

• Principal investigator: Tuba Kurt, MD, Associate Professor — Health Sciences University Bursa City Hospital, Department of Pediatric Rheumatology
• Study coordinator: Nur Şeyma Zengin, MD
• Email: nszengin37@hotmail.com
• Phone: +90 5064767328

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ravulizumab for children with IgA nephropathy or IgA vasculitis nephritis

  This trial will test whether intravenous ravulizumab is safe and changes disease markers in children aged 2 to under 18 with biopsy‑proven IgA nephropathy or IgA vasculitis nephritis.

  Recruiting at 13 sites Phase 3 Alexion Pharmaceuticals, Inc. · Palo Alto, California and 14 other locations · NCT07024563

• Which approved add-on drugs slow kidney decline in South-Asian adults with biopsy-proven IgA nephropathy?

  This trial will test whether adding one of several approved oral medications to standard care can slow kidney function loss over two years in South-Asian adults with biopsy-proven IgA nephropathy.

  Recruiting Phase 4 Christian Medical College, Vellore, India · Nadiād, Gujarat and 11 other locations · NCT06676384

• Treatment of pediatric kidney diseases with Sparsentan

  This study is testing if a new oral medication called Sparsentan can help children aged 1 to 18 with certain kidney diseases feel better and improve their condition over two years.

  Recruiting at 38 sites Phase 2 Travere Therapeutics, Inc. · Los Angeles, California and 46 other locations · NCT05003986

• Evaluating skin lesions in patients with various types of vasculitis

  This study is testing how skin lesions from different types of vasculitis look under a microscope to help doctors better understand and treat these conditions.

  Recruiting at 4 sites University of Pennsylvania · Los Angeles, California and 9 other locations · NCT03004326

• Collection of tissue samples for vasculitis research

  This study is collecting tissue samples from patients with vasculitis to see if they can help researchers understand the disease better and find new ways to diagnose and treat it.

  Recruiting at 3 sites University of Pennsylvania · Boston, Massachusetts and 7 other locations · NCT02967068

• Comparing treatments for isolated skin vasculitis

  This study is testing which of three common treatments—colchicine, dapsone, or azathioprine—works best for people with isolated skin vasculitis over a year.

  Recruiting at 7 sites Phase 2 University of Pennsylvania · Kansas City, Kansas and 15 other locations · NCT02939573

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.